Evidence map›Paper›PMID 30100728›Full record

ReviewTherapeutics and clinical risk management2018

Dendritic cell vaccines for high-grade gliomas.

Matthew E Eagles, Farshad Nassiri, Jetan H Badhiwala, Suganth Suppiah, Saleh A Almenawer, Gelareh Zadeh, Kenneth D Aldape

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutics and clinical risk management, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05707910 (A Phase I Study of the Efficacy and Safety of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors), which is not on this map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05707910 phase1active not recruitingnot on this mapstarted 2023, after this paper: background citation

A Phase I Study of the Efficacy and Safety of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

TypeinterventionalSponsorWest China HospitalRan2023 to 2027Enrolled6ConditionsMalignant TumorArmsEBV immunological agent
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Current Immunotherapeutic Approaches for Malignant Gliomas.Brain tumor research and treatment · 2022
    Review
  17. Review
  18. Metabolism and immunity in breast cancer.Frontiers of medicine · 2021
    Review
  19. Article
  20. Differentiation and Regulation of TFrontiers in immunology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Matthew E EaglesSection of Neurosurgery, Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada.
Farshad NassiriDivision of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada, jetan.badhiwala@mail.utoronto.ca.
Jetan H BadhiwalaDivision of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada, jetan.badhiwala@mail.utoronto.ca.
Suganth SuppiahDivision of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada, jetan.badhiwala@mail.utoronto.ca.
Saleh A AlmenawerDivision of Neurosurgery, Department of Surgery, McMaster University, Hamilton, ON, Canada.
Gelareh ZadehMacFeeters-Hamilton Neuro-Oncology Program, University Health Network, Toronto, ON, Canada.
Kenneth D AldapeMacFeeters-Hamilton Neuro-Oncology Program, University Health Network, Toronto, ON, Canada.
University Health Network · CAUniversity of Toronto · CAMcMaster University · CAUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is the most common and fatal primary adult brain tumor. To date, various promising chemotherapeutic regimens have been trialed for use in GBM; however, temozolomide (TMZ) therapy remains the only US Food and Drug Administration-approved first-line chemotherapeutic option for newly diagnosed GBM. Despite maximal therapy with surgery and combined concurrent chemoradiation and adjuvant TMZ therapy, the median overall survival remains approximately 14 months. Given the failure of conventional chemotherapeutic strategies in GBM, there has been renewed interest in the role of immunotherapy in GBM. Dendritic cells are immune antigen-presenting cells that play a role in both the innate and adaptive immune system, thereby making them prime vehicles for immunotherapy via dendritic cell vaccinations (DCVs) in various cancers. There is great enthusiasm surrounding the use of DCVs for GBM with multiple ongoing trials. In this review, we comprehensively summarize the safety, efficacy, and quality of life results from 33 trials reporting on DCV for high-grade gliomas.

Indexed as

dendritic cellsglioblastomagliomavaccine

Identifiers

PMID30100728
PMCPMC6067774
OpenAlexW2883891816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.